Skip to main content

Closed

INMB: INmune Bio, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+257.1% / yr

Operating margin0.0%

ROIC-204.8%

Financially safe

Stretched

Debt / equity0.08×

Interest coverage0.0×

Current ratio4.24×

INmune Bio, Inc.

INMBNASDAQ Capital Market·USD·Closed

INmune Bio, Inc.

INMBNASDAQ·USD·Closed

$1.75

−1.13%

$1.75

−$0.02 (1.13%)

52W Range

35thpctl

Volume

0.29×avg

Mkt Cap

46.52MUSD

P/E

-1.0TTM

Div Yield

–ann

52W Range

35thpctl

Volume

0.29×avg

Market Cap

46.52MUSD

P/E Ratio

-1.0TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings